Using a neonatal immunostimulant to reduce mortality and increase productivity in poultry farms

Informations projet

PROVICOL

N° de convention de subvention: 718986

DOI 10.3030/718986

Projet clôturé

Date de signature de la CE 17 Février 2016

Date de début 1 Mars 2016

Date de fin 31 Août 2016

Financé au titre de

• SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy

Coût total € 71 429,00

Contribution de l’UE € 50 000,00

Coordonné par

VITAMFERO SA
France

Objectif

VitamFero, an innovative French SME, is aiming to develop a new approach to protect chickens against infectious diseases during their first weeks of life. The PROVICOL project aims to induce a strong innate immune response in young chickens in order to protect them against a large panel of infectious diseases.

1 - PROVICOL will substantially reduce mortality and morbidity rates in chicken breeding thereby improving the overall breeding production process.
2 - This will also lead to a substantial decrease in the use of antibiotics in breeding establishments.
During the feasibility part (6 months) of PROVICOL, VitamFero will focus the study on technical matters (validation and optimisation of induced innate immune response) and on a business approach. The objective is to confirm, on the basis of previous encouraging results, the wider market opportunity for this product by conducting an economic feasibility study and elaborating a business plan in order to prepare for its marketing. This feasibility study will also validate the market strategy deployment and will improve the business impact of the project (pharmaco-economic study over 3 countries).

The PROVICOL project will generate an expected turnover of 426 million € (127millions € for VitamFero) within 10 years. Provicol is a key project for VitamFero and will act as a lever for the growth of the company, especially for an international commercial deployment.

Champ scientifique

• social sciences › sociology › demography › mortality
• medical and health sciences › health sciences › infectious diseases
• medical and health sciences › basic medicine › immunology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antibiotics
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › antibiotic resistance

Programme(s)

• H2020-EU.3.2. - SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy Main Programme
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Thème(s)

• SFS-08-2015-1 - Resource-efficient eco-innovative food production and processing

Appel à propositions

H2020-SMEInst-2014-2015

Voir d’autres projets de cet appel

Sous appel

H2020-SMEINST-1-2015

Régime de financement

SME-1 - SME instrument phase 1

Coordinateur

VITAMFERO SA

• Contribution nette de l'UE: € 50 000,00
• Adresse: RUE ANDRE LE NOTRE 8 ANGERS TECHNOPOLE ; 49000 ANGERS ; France
• PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui:
  Région
  Pays de la Loire › Pays de la Loire › Maine-et-Loire
• Région: Pays de la Loire › Pays de la Loire › Maine-et-Loire
• Type d’activité: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Coût total: € 71 429,00